Antiphopholipid antibodies and functional activated protein C resistance in patients with breast cancer during anthracycline-based chemotherapy administered through an intravenous port-catheter device

Clin Appl Thromb Hemost. 2014 Apr;20(3):338-40. doi: 10.1177/1076029613508598.
No abstract available

Publication types

  • Letter

MeSH terms

  • Activated Protein C Resistance / blood
  • Activated Protein C Resistance / metabolism*
  • Administration, Intravenous
  • Anthracyclines / administration & dosage
  • Anthracyclines / adverse effects
  • Antibodies, Antiphospholipid / blood
  • Antibodies, Antiphospholipid / metabolism*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Breast Neoplasms / blood
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / immunology*
  • Case-Control Studies
  • Female
  • Humans
  • Middle Aged

Substances

  • Anthracyclines
  • Antibodies, Antiphospholipid

Supplementary concepts

  • Thrombophilia due to Activated Protein C Resistance